02554nas a2200397   4500000000100000008004100001260001300042653001200055653002600067653002600093653001800119653002700137653003700164653003000201653001100231653002100242653002300263653001200286653000900298653002500307653001600332653001700348653001600365653001500381653001300396653002200409100000900431700001400440245009200454856005900546300001000605490001300615050003200628520148200660022001402142       2000                            d  c2000 Dec10aAnimals10aAnti-Bacterial Agents10aAnti-Infective Agents10aAza Compounds10aDisease Models, Animal10aDose-Response Relationship, Drug10aDrug Therapy, Combination10aFemale10aFluoroquinolones10aLeprostatic Agents10aleprosy10aMice10aMice, Inbred Strains10aMinocycline10aMoxifloxacin10aProbability10aQuinolines10aRifampin10aTreatment Outcome1 aJi B1 aGrosset J00aCombination of rifapentine-moxifloxacin-minocycline (PMM) for the treatment of leprosy.  uhttp://leprev.ilsl.br/pdfs/2000/v71s1/pdf/v71s1a17.pdf  aS81-70 v71 Suppl  aInfolep Library - available3 a<p>To further the development of a multidrug regimen for treatment of leprosy that is suitable for monthly administration and fully supervisable, the bactericidal activities against Mycobacterium leprae of HMR 3647 (HMR), moxifloxacin (MXFX) and rifapentine (RPT) were measured by the proportional bactericide technique in the mouse footpad system, and compared with those of the established antileprosy drugs clarithromycin (CLARI), ofloxacin (OFLO) and rifampicin (RMP). Administered in five daily doses of 100 mg per kg body weight, HMR appeared slightly more bactericidal than CLARI, but the difference did not attain statistical significance. Administered as single doses, MXFX in a dosage of 150 mg per kg was more active than OFLO in the same dosage, and displayed the same level of activity as RMP in a dosage of 10 mg per kg; the combination MXFX-minocycline (MINO) (MM) was more bactericidal than the combination OFLO-MINO (OM); RPT in a dosage of 10 mg per kg was more bactericidal than RMP administered in the same dosage, and even more active than the combination RMP-OFLO-MINO (ROM); the combination RPT-MXFX-MINO (PMM) killed 99.9% of viable M. leprae, and was slightly more bactericidal than was RPT alone, indicating that the combination PMM showed an additive effect against M. leprae. These promising results justify a clinical trial among lepromatous patients, in which MM is being compared with OM, and PMM with ROM, in terms of efficacy and tolerance.</p>  a0305-7518